What is it?
Developed and updated by the Stop TB Partnership’s Global Drug Facility, in close collaboration with the World Health Organization, the Global Fund, and USAID, the TB Medicines Dashboard is a visualization tool that measures policy and institutional coherence on selection, quality assurance, procurement, and use of TB medicines.
What does it include?
The dashboard organizes, stores, and displays TB medicines information from 13 different data sources in one easy-to-access place. Specific content includes:
- WHO Guidelines for Treatment and Prevention of TB
- WHO Model Essential Medicine Lists (EMLs), including submissions
- WHO Prequalification of Medicines List, and Expression of Interest
- Global Fund Expert Review Panel List of Medicines, including submissions
- GDF TB Medicines Catalog
How will it help?
- Identify areas of divergence across contributing institutions and provide a roadmap to guide actions toward improved alignment and efficiency;
- Track progress on development and quality assurance of new medicines and formulations toward expedited new product introduction and scale-up;
- Send clear, consistent signals to suppliers on the gaps in medicines and formulations that are not yet developed, as well as the medicines and formulations that are no longer needed;
- Support market consolidation and other market-shaping activities;
- Facilitate benchmarking and revision of national guidelines, EMLs, and procurement lists against global guidance documents; and,
- Support national procurement of WHO-recommended, affordable, quality-assured medicines.
How does it work?
- The dashboard has seven views: drug-resistant TB, drug-sensitive TB, and latent TB infection for adult and pediatric formulations, as well as a view with products that have been de-listed.
- Each view contains a list of medicines and its current status across the various guidance documents included in the dashboard.
- Click or hover over any dot to link to the primary data source, when applicable.
To download PDF versions of the dashboard or to see a detailed description of data sources and content, please go to the bottom of this page.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
If you have any comments or questions, please contact GDF directly by clicking here.
- TB Medicines Dashboard (all-in-one document)
- Adult Drug-Resistant TB Medicines Dashboard
- Adult Drug-Sensitive TB Medicines Dashboard
- Adult Latent TB Infection Medicines Dashboard
- Pediatric Drug-Resistant TB Medicines Dashboard
- Pediatric Drug-Sensitive TB Medicines Dashboard
- Pediatric Latent TB Infection Medicines Dashboard
- Products de-listed Medicines Dashboard
Description of data sources and content:
These are recommendations issued by the WHO Global TB Programme on the prevention, diagnosis and treatment of different forms of TB. When possible, the two most recent guidelines are included. Access the WHO Global TB Programme website here.
This section refers to the WHO Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc). Further information on the EMLs can be accessed here.
- EML submitted: An application to include the medicine on either the EML or EMLc (or both) has been submitted to the WHO Expert Committee on Selection and Use of Essential Medicines (biennial)
- EML (2017): The medicine is included on either the EML (20th edition) or EMLc (6th edition).
This section refers to the WHO Prequalification Programme (PQ). Further information on WHO PQ can be found here.
- WHO PQ EOI: The Expression of Interest (EOI) contains a list of all products eligible to be submitted and reviewed by WHO PQ.
- WHO PQ submitted: Indicates the dossiers that have been submitted and accepted for review by WHO PQ.
- WHO PQ listed: The medicine is listed in the products prequalified by WHO PQ.
Global Fund ERP
This section refers to the Global Fund’s Expert Review Panel (ERP). The ERP is meant to accelerate access to products while they are undergoing review by WHO PQ and/or a Stringent Regulatory Authority. Further information on the ERP can be found here.
- Global Fund EOI: The Expression of Interest (EOI) is published twice a year and contains a list of priority products that are eligible to be submitted and reviewed by the ERP.
- Global Fund ERP approved: Products approved by the ERP are included until they are either prequalified by WHO PQ, approved by a Stringent Regulatory Authority or are removed.
GDF facilitates access to high-quality TB medicines and diagnostics. Products indicated here are available from GDF. The full GDF Catalog is available here.